|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
66,620,000 |
Market
Cap: |
206.52(M) |
Last
Volume: |
14,666 |
Avg
Vol: |
14,626 |
52
Week Range: |
$2.93 - $7.84 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile MEI Pharma is a late-stage pharmaceutical company focused on the development and commercialization of cancer therapies to improve outcomes for patients. Co.'s portfolio of drug candidates includes three clinical-stage assets, including: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor; Voruciclib, an oral cyclin-dependent kinase 9 inhibitor; and ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
336,100 |
417,600 |
Total Buy Value |
$0 |
$0 |
$2,112,595 |
$2,130,933 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
6 |
7 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wood Steven D |
|
|
2024-05-17 |
4 |
A |
$3.17 |
$9,827 |
D/D |
3,100 |
4,359 |
|
- |
|
Flynn James P |
|
|
2024-05-16 |
4 |
A |
$3.16 |
$24,981 |
D/D |
7,900 |
7,900 |
|
- |
|
Wood Steven D |
|
|
2023-10-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
67,733 |
|
-39% |
|
Wood Steven D |
|
|
2023-10-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,259 |
|
-39% |
|
Ma-Weaver Jacob |
10% Owner |
|
2023-10-20 |
4 |
OE |
$7.00 |
$844,200 |
I/I |
120,600 |
611,440 |
|
- |
|
Winson Bruce Ross |
10% Owner |
|
2023-10-20 |
4 |
OE |
$7.00 |
$1,253,000 |
I/I |
179,000 |
1,093,188 |
|
- |
|
Ma-Weaver Jacob |
10% Owner |
|
2023-10-11 |
4 |
OE |
$7.00 |
$210,000 |
I/I |
30,000 |
490,840 |
|
- |
|
Winson Bruce Ross |
10% Owner |
|
2023-10-11 |
4 |
OE |
$7.00 |
$350,000 |
I/I |
50,000 |
914,188 |
|
- |
|
Ma-Weaver Jacob |
10% Owner |
|
2023-09-22 |
4 |
B |
$6.85 |
$219,554 |
I/I |
32,040 |
460,840 |
1.5 |
-40% |
|
Winson Bruce Ross |
10% Owner |
|
2023-09-22 |
4 |
B |
$6.85 |
$329,331 |
I/I |
48,060 |
864,188 |
1.5 |
-40% |
|
Ma-Weaver Jacob |
10% Owner |
|
2023-09-21 |
4 |
B |
$6.46 |
$144,740 |
I/I |
22,400 |
428,800 |
1.5 |
-32% |
|
Winson Bruce Ross |
10% Owner |
|
2023-09-21 |
4 |
B |
$6.46 |
$217,110 |
I/I |
33,600 |
816,128 |
1.5 |
-32% |
|
Ma-Weaver Jacob |
10% Owner |
|
2023-09-20 |
4 |
B |
$6.01 |
$480,744 |
I/I |
80,000 |
406,400 |
1.5 |
-26% |
|
Winson Bruce Ross |
10% Owner |
|
2023-09-20 |
4 |
B |
$6.01 |
$721,116 |
I/I |
120,000 |
782,528 |
1.5 |
-26% |
|
Ma-Weaver Jacob |
10% Owner |
|
2023-05-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
326,400 |
|
-5% |
|
Winson Bruce Ross |
10% Owner |
|
2023-05-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
662,528 |
|
-5% |
|
Baltic Charles V. Iii |
Director |
|
2023-02-28 |
4 |
B |
$0.23 |
$18,338 |
D/D |
81,500 |
105,750 |
2.39 |
- |
|
Ghalie Richard G |
Chief Medical Officer |
|
2022-07-05 |
4 |
D |
$0.54 |
$4,426 |
D/D |
(8,196) |
28,927 |
|
- |
|
Gold Daniel P Phd |
Chief Executive Officer |
|
2021-07-02 |
4 |
D |
$2.94 |
$121,481 |
D/D |
(41,320) |
417,312 |
|
- |
|
Urso David M |
Chief Operating Officer & GC |
|
2021-07-02 |
4 |
D |
$2.94 |
$72,986 |
D/D |
(24,825) |
49,281 |
|
- |
|
Gold Daniel P Phd |
Chief Executive Officer |
|
2021-05-25 |
4 |
OE |
$2.52 |
$12,600 |
D/D |
5,000 |
458,632 |
|
- |
|
Driscoll Frederick W |
Director |
|
2021-02-23 |
4 |
S |
$4.03 |
$100,625 |
D/D |
(25,000) |
37,500 |
|
- |
|
Gold Daniel P Phd |
Chief Executive Officer |
|
2020-07-23 |
4 |
OE |
$1.57 |
$18,840 |
D/D |
12,000 |
453,632 |
|
- |
|
Urso David M |
Chief Operating Officer & GC |
|
2020-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
74,106 |
|
- |
|
Gold Daniel P Phd |
Chief Executive Officer |
|
2020-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
80,000 |
441,632 |
|
- |
|
56 Records found
|
|
Page 1 of 3 |
|
|